Skip To Main Content
Brian Barnett on Muck Rack

Brian Barnett

As seen in: JAMA (The Journal of the American Medical Association), JAMA Psychiatry, JAMA: Journal of the American Medical Association, Mary Ann Liebert, Inc., Healio, American Journal of Public Health, Psychiatric News, PsychiatryOnline, Becker's Behavioral Health
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brian

Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB

|
By Brian Barnett, Franklin King
| JAMA Psychiatry Verified
Tiffany Farchione, MD, Director of the US Food and Drug Administration’s (FDA) Division of Psychiatry, recently told an audience that “Fully a third of my workload at this point [is] just reviewing psychedelic [investigational new drug applications].”1 The breadth and pace of today’s pharmaceutical development of these Schedule I substances may be unprecedented, yet a Schedule I substance securing FDA approval is not.
Open in Who Shared Issue with article?

Strengthening Safeguards for Psychiatric Uses of Ketamine

|
By Brian Barnett, Roger D. Weiss, Gerard Sanacora
| jamanetwork.com
Strengthening Safeguards for Psychiatric Uses of Ketamine In recent years, off-label use of ketamine has surged in the US. Data from more than 125 million patients indicate that ketamine prescriptions grew from 0.55 per 100 000 people in 2017 to 3.01 per 100 000 people in 2022—a 5.5-fold increase.1 The proportion of patients prescribed ketamine with billing diagnoses of depression increased from 5.3% to 28.3% during that period.1
Open in Who Shared Issue with article?

Eliminating the Medicare Coverage Gap for Intranasal Naloxone and Nicotine Replacement Therapy

|
By Robert A. Kleinman, Temerty Faculty, Brian Barnett
| JAMA: Journal of the American Medical Association Verified
Eliminating the Medicare Coverage Gap for Intranasal Naloxone and Nicotine Replacement Therapy Opioid and tobacco use disorders are leading causes of preventable deaths in the US.
Open in Who Shared Issue with article?
See all 14 articles